George Mammen, MD
Basic profileCalifornia Department of Toxic Substances Control
George Mammen is a Cardiology physician affiliated with California Department of Toxic Substances Control. OpenAlex indexes 24 publications with 1,872 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10496 Katy Fwy Ste 130
Houston, TX 77043
Telephone
713-464-2928Registry record last updated 4 Oct 2018.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202512 payments
- Edwards Lifesciences CorporationProgram year20251 payment
- Amgen Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.3%Beta blocker20.5%Metoprolol Succinate55%Carvedilol23%Metoprolol Tartrate8%Bisoprolol Fumarate5%Atenolol4%Nebivolol Hcl3%Propranolol Hcl1%Labetalol Hcl1%Bisoprolol-Hydrochlorothiazide1%Sotalol1%Part D<11 patientsStatin15.8%Atorvastatin Calcium59%Rosuvastatin Calcium35%Pravastatin Sodium4%Simvastatin2%Part D≥287 patients+ 19 more classes in this area
Blood & clotting
12.1%Factor Xa inhibitor7.2%Eliquis66%Xarelto34%Part D≥124 patientsP2Y12 inhibitor4.2%Clopidogrel95%Brilinta5%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1%Proton pump inhibitor0.6%Pantoprazole Sodium71%Omeprazole29%Part D<11 patientsPotassium supplement0.4%Potassium Chloride100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cannabis for pain in orthopedics: a systematic review focusing on study methodology
Canadian Journal of Surgery
2019 - Association of Cannabis With Long-Term Clinical Symptoms in Anxiety and Mood Disorders
The Journal of Clinical Psychiatry
2018
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”